Cell Signaling Technology (CST)’s Post

🔬Unlocking Insights into Fibrosis: The high-throughput high-sensitivity FMT Assay This assay provides critical insights into fibrotic diseases, outlining the importance of using culture conditions that promote fibroblast activation and matrix deposition for accurate protein detection and quantification results. 🔍Why Choose Newcells’ Advanced FMT Assay? ✔️High sensitivity: Accurately select which compound to progress to target idiopathic pulmonary fibrosis (IPF) and fibrosing lung disease. ✔️High-Throughput Imaging: Reliable and rapid quantification using a 384-well format. ✔️Translational Insights: 4 data otuputs. Establish a link between RNA expression and protein expression changes. Learn more here: https://lnkd.in/ePdxzcZm #Newcells #Lung #FibrosisResearch

Exciting progress in the fight against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as NAFLD! Researchers have identified diagnostic signatures for key histological features of the disease using serum protein scanning. These proteomic models could pave the way for a non-invasive "liquid biopsy" approach, improving how we diagnose and monitor MASLD. 📊 Dive into the full study to learn more about this groundbreaking research and its implications for future treatments. Read more here: https://ow.ly/647X50SU7n7 #NAFLD #LiverHealth #MedicalResearch #Proteomics #LiquidBiopsy #UCSDACTRI #UCSDHealth #UCSanDiegoHealth #MASLD

Join us for our webinar discussing metabolomic profiling of Parkinson's disease. Our expert will detail how their study compared treated and untreated patient's #metabolomic profile and incorporated #bioinformatics to uncover mechanisms of disease. https://mtbln.co/bboc0i

Discover the pivotal role of biomarkers like procalcitonin and NT-proBNP in early detection and management. Secure your spot now for invaluable insights from industry experts. Register Today https://bit.ly/435C6Io #PediatricSepsis #Webinar #EarlyDetection #ResponseBio

Just come out in #ACSChemNeurosci our last paper on dual GSK-3β/HDACs inhibitors as a potential therapeutic to treat Alzheimer’s disease! Take a look!

Earlier this week, we tested your knowledge about a molecule that is a key mediator of inflammation and cytokine regulation. If you guessed JAK1 and/or JAK2, members of the Janus kinase (JAK) family, you guessed correctly! Dysregulation of the JAK/STAT pathway plays a key role in various cancers and autoimmune diseases. Learn more about the investigation of JAK inhibition at Incyte. #UnderTheMicroscope https://bit.ly/492a3uV

We need better biomarkers for identifying mitochondrial disease as lactate has been shown to have both low sensitivity and specificity despite often being seen as indicative or reassuring. We welcome this work from Fernandez et al exploring the use of growth differentiation factor 15 as a biomarker in mtDNA related disorders. The clinical utility in hospital-wide use of growth differentiation factor 15 as a biomarker for mitochondrial DNA-related disorders Andrea Cortes Fernandez, Jane Estrella, Devin Oglesbee, Austin Larson, Johan Van Hove https://lnkd.in/e9G6Tqmt #mitodisease #mitochondria

Béatrice Gulbis is presenting the 2 Recommendations that are under development by ERN-EuroBloodNet: on Diagnosis of rare hemolytic anaemia (in collaboration with @EHA_Hematology), and on sickle cell disease. Moreover, the Clinical practice guideline on diagnosis and management of Pyruvate kinase deficiency was published on March 2024! #EBNMeeting2024 

#ACROHighlights [Featured Product] 🔬 Discover the Potential of TL1A/DR3 Pathway in Autoimmune Disease Treatment! The TL1A/DR3 pathway plays a key role in regulating inflammation and its dysregulation has been implicated in many autoimmune diseases. We offer a range of TL1A and DR3 proteins and a TL1A-stable cell line to support your research into developing novel therapies targeting this pathway. Explore various species, tags, and labels to customize your experiments. Don't miss out on this exciting avenue for advancing your autoimmune disease research! 💡 👉 Check out our TL1A/DR3 products here: https://smpl.is/8wgn0 #AutoimmuneDiseaseResearch #TL1A #DR3Pathway #BiotechSolutions

There is an urgent need in creating better treatment options for cardiovascular & Metabolic Diseases. Learn how Discovery | Charles River can help to progress your program : #Cardiovascular and metabolic diseases are among the leading causes of death and disability in the developed world, and a growing concern in developing nations. Check out our refreshed cardiovascular and metabolic disease drug discovery service portfolio, including innovative target identification and validation platforms, complex in vitro assays, and in vivo cardiovascular and metabolic models, all of which assist in translating basic research to clinical reality. https://okt.to/Cu4xAV